Venlo, The Netherlands - June 18, 2008 - QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced a significant expansion of its EpiTect product portfolio for epigenetics, one of the most dynamic areas in life sciences. With the five new products, QIAGEN now offers standardized solutions covering all steps of epigenetic research processes in molecular diagnostics, pharma and life sciences. By removing existing bottlenecks in epigenetic research, the new products are expected to advance progress in the development of new diagnostics and therapeutics for cancer and other diseases.
